LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Cerrado

2.85 -0.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.81

Máximo

2.94

Métricas clave
By Trading Economics
Ingresos	64M 57M
Ventas	65M 67M
P/B Media del Sector	7.135 49.8
Margen de beneficios	84.425
Empleados	75
EBITDA	63M 56M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+69.2% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	38M 250M
Apertura anterior	3.2
Cierre anterior	2.85

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.25 / 1.48 Soporte y Resistencia

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 may 2026, 23:55 UTC

Ganancias

Review & Preview: Still Going Strong -- Barrons.com

8 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 20:49 UTC

Ganancias

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 may 2026, 20:25 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Net $115M

8 may 2026, 19:20 UTC

Charlas de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 may 2026, 19:18 UTC

Ganancias

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 may 2026, 19:16 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:08 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:05 UTC

Ganancias

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 may 2026, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 may 2026, 18:51 UTC

Ganancias

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 may 2026, 18:49 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 18:41 UTC

Ganancias

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 may 2026, 17:14 UTC

Ganancias

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 may 2026, 17:04 UTC

Charlas de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 may 2026, 15:36 UTC

Charlas de Mercado

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 may 2026, 15:20 UTC

Charlas de Mercado

'Altcoin Season' Indicator on the Rise -- Market Talk

8 may 2026, 15:20 UTC

Charlas de Mercado

Ganancias

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 may 2026, 15:05 UTC

Charlas de Mercado

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 may 2026, 14:42 UTC

Charlas de Mercado

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 may 2026, 14:39 UTC

Charlas de Mercado

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

69.2% repunte

Estimación a 12 Meses

Media 4.67 USD 69.2%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.25 / 1.48Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.